Last Updated on October 10, 2024 by The Health Master
Ahmedabad: Zydus Lifesciences Limited‘s U.S. subsidiary, Zydus Pharmaceuticals (USA) Inc., has recently announced that the company has received tentative approval from the United States Food and Drug Administration (USFDA) to market levothyroxine sodium for injection, 100 mcg/vial, 200 mcg/vial, and 500 mcg/vial. Levothyroxine Sodium Injection is manufactured by Fresenius Kabi USA, LLC.
Myxedema coma is an extreme or decompensated form of hypothyroidism and, while uncommon, is potentially lethal.
Primary symptoms of the disease are low body temperature and altered mental status.
The injection of levothyroxine sodium is used to treat myxedema coma.
The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara, India.
According to IQVIA data (IQVIA MAT Sep 2022), the annual sales of levothyroxine sodium injection in the United States were USD 45.2 million.
The group now has 334 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences Limited, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company headquartered in Ahmedabad.
The company is primarily engaged in the manufacture of generic drugs.
Zydus group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim in India and in the US and Brazil.
Zydus‘ global business has a strong presence in the regulated markets of the US, Europe (France and Spain), and the high-profile markets of Latin America and South Africa.
It is also present in a big way in 25 other emerging markets worldwide.
USFDA gives nod for Nifedipine ER tablets
USFDA gives nod for Amphotericin B Liposome Injection
USFDA gives approval for Potassium-deficiency drug
USFDA gives final approval for Cyclophosphamide capsules
USFDA gives nod to market this generic Antibiotic Drug
USFDA gives tentative approval for Drospirenone tablets
CDSCO gives nod to Dapagliflozin Tablets
Pharmacists deserve more recognition for their work
USFDA designates Cipla’s Goa plant as ‘OAI’
USFDA declines to approve this Lung Cancer drug
NPPA fixes Retail Price of 40 formulations: November 2022
IPC adds one IP Reference Standard & 20 new impurities to IP 2022
Govt issues draft notification to amend NDCTR, 2019
Haryana: Sathi app launched to check Drugs abuse
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
